Glecaprevir / Pibrentasvir

Rifampin

Contraindicated.

Available pharmaceutical opinion

Document made available to the pharmacist to communicate a drug interaction to the doctor.

DOWNLOAD
Mechanism

Rifampin at steady state may induce CYP 3A4 and P-gp and decrease the plasma concentration of Glecaprevir / Pibrentasvir.

Glecaprevir / Pibrentasvir

Pharmacodynamic effects

Possible decrease of clinical efficacy.

Recommendations

Avoid association.

Alternative solution(s)

Rifampin

Pharmacodynamic effects

Recommendations

Alternative solution(s)

Monitor

Tests

Pharmacokinetic parameters
Parameters
Reference number
# patients
HCV
Dose
Frequency
AUC
Cmax
Glecaprevir / Pibrentasvir
3373
12
-
300/120 mg
QD
- 88%/- 87%
- 86%/- 83%
Rifampin
3373
12
-
600 mg
QD
 
 
Comment

Ref #3373 : The first dose of rifampin increased the AUC and Cmax of glecaprevir by 8.55 and 6.52-fold, respectively. Concentrations of pibrentasvir remained unchanged. This increase is due to OATP1B1/3 inhibition by rifampin.

Reference
  • 3373
    Glecaprevir/Pibrentasvir (Maviret), Abbvie, Québec, Canada, 19 février 2020.